<DOC>
	<DOCNO>NCT01125488</DOCNO>
	<brief_summary>The recurrence rate endometriosis report woman 5 year therapy gonadotropin release hormone ( GnRH ) agonist 74 % severe disease . No strategies prevent recurrence endometriosis uniformly successful . Local progesterone treatment endometriosis-associated dysmenorrhea levonorgestrel-releasing intrauterine system ( LNG-IUS ) 12 month result significant reduction dysmenorrhea , pelvic pain dyspareunia ; high degree patient satisfaction ; significant reduction volume rectovaginal endometriotic nodule . LNG-IUS may become important option long-term medical suppression endometriosis . Based literature review , I hypothesize maintenance therapy LNG-IUS conjunction GnRH agonist could lower recurrence rate endometriosis conservative surgery . We try answer question whether maintenance therapy LNG-IUS conjunction GnRH agonist could lower recurrence rate thus extend symptom-free interval ( menorrhagia dysmenorrhea ) compare GnRH agonist alone conservative surgery severe endometriosis case .</brief_summary>
	<brief_title>Maintenance Therapy Levonorgestrel-releasing Intrauterine System ( LNG-IUS ) Prevent Recurrence Symptomatic Endometriosis After Conservative Surgery</brief_title>
	<detailed_description>Participants : This post-surgical medical therapy trial undertaken among patient moderate-severe symptomatic endometriosis ( rASRM score &gt; 16 , accord American Society Reproductive Medicine ) adenomyosis . Symptomatic endometriosis mean menorrhagia dysmenorrhea . All patient surgically treat conservative approach ( mean preserve uterus ovary ) . Interventions : In patient , prescribe 600 mg elemental Ca 400 IU vitamin D ( bid ) . The first group patient receive LNG-IUS 5 year GnRH agonist ( triptorelin 3.75 mg , sc q28day ) 24 week . The second group patient receive GnRH agonist ( triptorelin 3.75 mg , sc q28day ) alone 24 week . Patients evaluate every month 24 week , 3,6,9,12,15,18,21,24 month end medical treatment . Objectives outcome : The main objective trial ass clinical efficacy LNG-IUS maintenance therapy prevent recurrence endometriosis . Thus primary outcome measure trial recurrence rate endometriosis . During trial , recurrence define elevation CA125 ( 6 ) endometriosis lesion sonography symptom suggest endometriosis include menorrhagia dysmenorrhea . The pain score diary base visual analogue scale patient record occurrence intensity pain daily . VAS consist subjective evaluation pain scale 10 0 pain 10 severe pain ( 7 ) . Bleeding menorrhagia assess : 0= bleeding ; 1=spotting ( light bleed require sanitary protection ) ; 2=light bleeding ( light bleed require sanitary protection ) ; 3=normal bleeding ( bleed similar normal menstrual blood flow ) ; 4=heavy bleeding ( bleed exceed normal menstrual blood flow ) . No bleeding define 30 consecutive day bleed score 0 ( 8 ) . Randomization process : Treatment allocation perform accordance computer-generated randomization sequence use number , seal envelope . Evaluation efficacy : Sample size : In calculate sample size require , primary assessment recurrence rate . A 31 % recurrence rate laparoscopic reproductive surgery post-surgical treatment GnRH agonist report ( 9 ) . We expect decrease recurrence rate laparoscopic conservative surgery post-surgical treatment GnRH agonist plus LNG-IUS . A difference 25 % allocate treatment consider significant . To 90 % chance detect difference overall significant level 5 % , 40 patient group require . Endpoints : We follow patient 2 year , end GnRH agonist medical treatment . Thus primary outcome measure trial recurrence rate endometriosis . The main objective trial ass clinical efficacy LNG-IUS maintenance therapy prevent recurrence endometriosis . Statistical analysis plan : The cumulative proportion recurrence plot percent recurrence function time estimate method Kaplan Meier . The survival curve allocate treatment compare log-rank test . For quantitative variable normal distribution , parametric t-test use ; case variable , non-parametric Mann-Whitney test apply . For qualitative variable , x2-test Fisher 's exact test use . For dependent variable numerical score refer long-term measurement , multivariate analysis variance ( MANOVA ) use .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Patients moderatesevere symptomatic endometriosis ( rASRM score &gt; 16 ) accord American Society Reproductive Medicine ) adenomyosis . Symptomatic endometriosis mean menorrhagia dysmenorrhea . All patient surgically treat conservative approach . Levels serum CA125 high normal range . Further desire child bear future 3 year . Any treatment endometriosis within previous 2 month . Any concomitant disease establish cause chronic pelvic pain anemia ( Thalassemia anemia , inflammation sequela , myoma , pelvic congestion etc )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Maintenance therapy</keyword>
	<keyword>LNG-IUS</keyword>
	<keyword>recurrence , endometriosis</keyword>
	<keyword>Recurrence</keyword>
</DOC>